This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and
safe in the treatment of patients with MDD.
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Research Site, Birmingham, Alabama, United States
Research Site, Scottsdale, Arizona, United States
Research Site, Beverly Hills, California, United States
Research Site, San Diego, California, United States
Research Site, Sherman Oaks, California, United States
Research Site, Wildomar, California, United States
Research Site, Bradenton, Florida, United States
Research Site, Orlando, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Boca Raton, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, West Palm Beach, Florida, United States
Research Site, Edwardsville, Illinois, United States
Research Site, Lake Charles, Louisiana, United States
Research Site, Baltimore, Maryland, United States
Research Site, Haverhill, Massachusetts, United States
Research Site, Okemos, Michigan, United States
Research Site, St. Paul, Minnesota, United States
Research Site, St. Louis, Missouri, United States
Research Site, Princeton, New Jersey, United States
Research Site, Albuquerque, New Mexico, United States
Research Site, New York City, New York, United States
Research Site, Dayton, Ohio, United States
Research Site, Mayfield Village, Ohio, United States
Research Site, Oklahoma City, Oklahoma, United States
Research Site, Salem, Oregon, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Columbia, South Carolina, United States
Research Site, Memphis, Tennessee, United States
Research Site, Houston, Texas, United States
Research Site, Salt Lake City, Utah, United States
Research Site, Richmond, Virginia, United States
Research Site, Kirkland, Washington, United States
Research Site, Morgantown, West Virginia, United States